Rhinovirus Infections (Infectious Disease) - Drugs In Development, 2021

July 2021 | 69 pages | ID: RF9CAC57B92FEN
Global Markets Direct

Abstracts

Rhinovirus Infections (Infectious Disease) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhinovirus Infections - Drugs In Development, 2021, provides an overview of the Rhinovirus Infections (Infectious Disease) pipeline landscape.

Rhinoviruses are common cause of the common cold. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhinovirus Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Rhinovirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhinovirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rhinovirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 11 and 7 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Rhinovirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Rhinovirus Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Rhinovirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Rhinovirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Rhinovirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Rhinovirus Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Rhinovirus Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Rhinovirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Rhinovirus Infections - Overview
Rhinovirus Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rhinovirus Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rhinovirus Infections - Companies Involved in Therapeutics Development
Apollo Therapeutics LLC
Arum Therapeutics Inc
AstraZeneca Plc
Biological Mimetics Inc
Celestial Therapeutics Inc
Collaborations Pharmaceuticals Inc
Ena Respiratory Pty Ltd
Enyo Pharma SA
G.ST Antivirals GmbH
Gilead Sciences Inc
Haplogen GmbH
Harbins Ruhr Bioscience Inc
Kyorin Pharmaceutical Co Ltd
Meissa Vaccines Inc
PrEP Biopharm Ltd
Romark Laboratories LC
Sagimet Biosciences
Secarna Pharmaceuticals GmbH & Co KG
ST Pharm Co Ltd
Symmune Therapeutics LLC
Viravaxx AG
Rhinovirus Infections - Drug Profiles

2-DG - DRUG PROFILE

Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide for Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ART-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNT-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Enterovirus Infections and Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Rhinovirus and Coxsackievirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human rhinovirus (polyvalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INNA-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPRA-218 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitazoxanide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitazoxanide CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polymer for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PrEP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rhinovirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 3C Protease for Rhinovirus Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PLA2G16 for Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sphingosine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVB-3567 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rhinovirus Infections - Dormant Projects
Rhinovirus Infections - Discontinued Products
Rhinovirus Infections - Product Development Milestones
Featured News & Press Releases
May 10, 2017: Meissa announces award of NIH SBIR grant to support development of multivalent human rhinovirus vaccine candidate
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Rhinovirus Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Rhinovirus Infections - Pipeline by Apollo Therapeutics LLC, 2021
Rhinovirus Infections - Pipeline by Arum Therapeutics Inc, 2021
Rhinovirus Infections - Pipeline by AstraZeneca Plc, 2021
Rhinovirus Infections - Pipeline by Biological Mimetics Inc, 2021
Rhinovirus Infections - Pipeline by Celestial Therapeutics Inc, 2021
Rhinovirus Infections - Pipeline by Collaborations Pharmaceuticals Inc, 2021
Rhinovirus Infections - Pipeline by Ena Respiratory Pty Ltd, 2021
Rhinovirus Infections - Pipeline by Enyo Pharma SA, 2021
Rhinovirus Infections - Pipeline by G.ST Antivirals GmbH, 2021
Rhinovirus Infections - Pipeline by Gilead Sciences Inc, 2021
Rhinovirus Infections - Pipeline by Haplogen GmbH, 2021
Rhinovirus Infections - Pipeline by Harbins Ruhr Bioscience Inc, 2021
Rhinovirus Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, 2021
Rhinovirus Infections - Pipeline by Meissa Vaccines Inc, 2021
Rhinovirus Infections - Pipeline by PrEP Biopharm Ltd, 2021
Rhinovirus Infections - Pipeline by Romark Laboratories LC, 2021
Rhinovirus Infections - Pipeline by Sagimet Biosciences, 2021
Rhinovirus Infections - Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2021
Rhinovirus Infections - Pipeline by ST Pharm Co Ltd, 2021
Rhinovirus Infections - Pipeline by Symmune Therapeutics LLC, 2021
Rhinovirus Infections - Pipeline by Viravaxx AG, 2021
Rhinovirus Infections - Dormant Projects, 2021
Rhinovirus Infections - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Rhinovirus Infections, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021